Vitamin D Supplementation in Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 15, 2021

Study Completion Date

May 15, 2021

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Vitamin D3

Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).

Trial Locations (16)

10032

Columbia University, New York

Unknown

Dignity Health Medical Foundation, Carmichael

University of California, San Francisco, San Francisco

Stanford University, Stanford

Yale University, New Haven

Anne Arundel Health System Research Institute, Annapolis

Johns Hopkins University School of Medicine, Baltimore

University of Massachusetts, Worcester

Washington University St. Louis, St Louis

Mount Sinai School of Medicine, New York

University of Rochester, Rochester

Cleveland Clinic, Cleveland

Oregon Health Sciences University, Portland

University of Pennsylvania, Philadelphia

University of Virginia, Charlottesville

Swedish Medical Center, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

University of Pennsylvania

OTHER

collaborator

Yale University

OTHER

collaborator

The Cleveland Clinic

OTHER

collaborator

University of Rochester

OTHER

collaborator

Stanford University

OTHER

collaborator

University of Virginia

OTHER

collaborator

Swedish Medical Center

OTHER

collaborator

Anne Arundel Health System Research Institute

OTHER

collaborator

Columbia University

OTHER

collaborator

University of Massachusetts, Worcester

OTHER

collaborator

Dignity Health

OTHER

lead

Johns Hopkins University

OTHER

NCT01490502 - Vitamin D Supplementation in Multiple Sclerosis | Biotech Hunter | Biotech Hunter